Director Sells $4.95 Million in Krystal Biotech Stock Following Option Exercise
KRYS has more than doubled off its 52-week low of $122.8.
Summary
A Krystal Biotech director sold approximately $4.95 million worth of common stock after exercising options, representing a significant disposition of shares.
Key Events · Ownership and Investor Activity · KRYS
-
Director Sells Shares
Director Dino A. Rossi disposed of 18,950 shares of Krystal Biotech common stock in open market transactions.
-
Significant Proceeds Generated
The open market sales generated approximately $4,953,694.15 for the director.
-
Option Exercise Preceded Sale
The sales followed the exercise of options to acquire 18,950 shares at a strike price of $8.79 per share.
Analysis · KRYS · Life Sciences
Director Dino A. Rossi executed a significant disposition of Krystal Biotech shares, selling approximately $4.95 million worth of common stock on the open market. This transaction followed the exercise of options to acquire the same number of shares at a much lower strike price. While such 'exercise and sell' transactions are common for liquidity or diversification, the substantial dollar value of this sale by a director, occurring shortly after the company reported strong financial results and preliminary revenue, could be interpreted as a lack of conviction or a strategic move to lock in gains. This sale contributes to a broader trend of net distribution by insiders over the last 90 days.
How filings like this one have moved
In the 30 days to Sep 23, 2026, 29.1% of the 1683 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.32%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, KRYS was trading at $274.59 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8B. The 52-week trading range was $122.80 to $298.30. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.